Microvascular complications in the heart and kidney are strongly associated with an overall rise in inflammation. Annexin A1 (ANXA1) is an endogenous anti-inflammatory molecule that limits and resolves inflammation. In this study, we have used a bedside to bench approach to investigate: (1) ANXA1 levels in individuals with type 1 diabetes; (2) the role of endogenous ANXA1 in nephropathy and cardiomyopathy in experimental type 1 diabetes; and (3) whether treatment with human recombinant ANXA1 attenuates nephropathy and cardiomyopathy in a murine model of type 1 diabetes.
Annexin A1 attenuates microvascular complications through restoration of Akt signalling in a murine model of type 1 diabetes / Purvis, Gareth S D; Chiazza, Fausto; Chen, Jianmin; Azevedo-Loiola, Rodrigo; Martin, Lukas; Kusters, Dennis H M; Reutelingsperger, Chris; Fountoulakis, Nikolaos; Gnudi, Luigi; Yaqoob, Muhammed M; Collino, Massimo; Thiemermann, Christoph; Solito, Egle. - In: DIABETOLOGIA. - ISSN 0012-186X. - 61:2(2018), pp. 482-495. [10.1007/s00125-017-4469-y]
Annexin A1 attenuates microvascular complications through restoration of Akt signalling in a murine model of type 1 diabetes
Solito, Egle
2018
Abstract
Microvascular complications in the heart and kidney are strongly associated with an overall rise in inflammation. Annexin A1 (ANXA1) is an endogenous anti-inflammatory molecule that limits and resolves inflammation. In this study, we have used a bedside to bench approach to investigate: (1) ANXA1 levels in individuals with type 1 diabetes; (2) the role of endogenous ANXA1 in nephropathy and cardiomyopathy in experimental type 1 diabetes; and (3) whether treatment with human recombinant ANXA1 attenuates nephropathy and cardiomyopathy in a murine model of type 1 diabetes.I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.
